Literature DB >> 15740947

Does Down syndrome affect the long-term results of complete atrioventricular septal defect when the defect is repaired during the first year of life?

Munetaka Masuda1, Hideaki Kado, Yoshihisa Tanoue, Koji Fukae, Tatsushi Onzuka, Yuichiro Shiokawa, Toshihiko Shirota, Hisataka Yasui.   

Abstract

BACKGROUND: Down syndrome is known to affect the natural history of complete atrioventricular septal defect. We analyzed whether Down syndrome affect the long-term results of complete atrioventricular septal defect when the defect is repaired during the first year of life.
METHODS: Repairs of complete atrioventricular septal defect were performed in 64 infants. Thirty-four infants were associated with Down syndrome, while the other 30 were non-Down patients.
RESULTS: Complete follow-up rate was 95% with mean follow-up period of 99+/-47 months (maximum 169 months) in Down patients and 80+/-64 months (maximum 213 months) in non-Down patients. There was one operative death in each group (mortality rate of 2.9% in Down patients and 3.3% in non-Down patients), and three patients died at the late phase (one in Down patients and two in non-Down patients). Five patients underwent re-operation due to postoperative left atrioventricular valve regurgitation (one in Down patients and four in non-Down patients). Freedom from re-operation for left atrioventricular valve regurgitation and actuarial survival rate at 13 years were 96+/-4 and 94+/-4% in Down patients and 85+/-7 and 90+/-5% in non-Down patients (not significantly different).
CONCLUSIONS: Down syndrome does not affect the long-term results of complete atrioventricular septal defect when the defect is repaired during the first year of life.

Entities:  

Mesh:

Year:  2004        PMID: 15740947     DOI: 10.1016/j.ejcts.2004.11.027

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  8 in total

1.  Diagnosis and management of Down syndrome.

Authors:  Neerja Agarwal Gupta; Madhulika Kabra
Journal:  Indian J Pediatr       Date:  2013-10-15       Impact factor: 1.967

2.  Management of pulmonary hypertension in Down syndrome.

Authors:  Amy Hawkins; Simon Langton-Hewer; John Henderson; Robert Michael Tulloh
Journal:  Eur J Pediatr       Date:  2011-01-04       Impact factor: 3.183

3.  Early outcomes and prognostic factors for left atrioventricular valve reoperation after primary atrioventricular septal defect repair.

Authors:  Sonali S Patel; Trudy L Burns; Lazaros Kochilas
Journal:  Pediatr Cardiol       Date:  2011-09-11       Impact factor: 1.655

4.  Long-Term Survival and Causes of Death in Children with Trisomy 21 After Congenital Heart Surgery.

Authors:  Jennifer K Peterson; Lazaros K Kochilas; Jessica Knight; Courtney McCracken; Amanda S Thomas; James H Moller; Shaun P Setty
Journal:  J Pediatr       Date:  2020-12-24       Impact factor: 4.406

5.  Outcomes when congenital heart disease is diagnosed antenatally versus postnatally in the UK: a retrospective population-based study.

Authors:  Lewis K Peake; Elizabeth S Draper; Judith L S Budd; David Field
Journal:  BMC Pediatr       Date:  2015-05-16       Impact factor: 2.125

6.  Early Complications After Percutaneous Closure of Atrial Septal Defect in Infants with Procedural Weight Less than 15 kg.

Authors:  Gustaf Tanghöj; Michal Odermarsky; Estelle Naumburg; Petru Liuba
Journal:  Pediatr Cardiol       Date:  2016-11-11       Impact factor: 1.655

7.  Outcomes of surgical repair of complete atrioventricular canal defect in patients younger than 2 years of age.

Authors:  Mohannad Ali Dawary; Faisal Dkhalallah Alshamdin; Louai Hassan Alkhalaf; Ahmed Othman Alkhamis; Fareed Ahmed Khouqeer
Journal:  Ann Saudi Med       Date:  2019-12-05       Impact factor: 1.526

Review 8.  New Molecular and Organelle Alterations Linked to Down Syndrome Heart Disease.

Authors:  Leslye Venegas-Zamora; Francisco Bravo-Acuña; Francisco Sigcho; Wileidy Gomez; José Bustamante-Salazar; Zully Pedrozo; Valentina Parra
Journal:  Front Genet       Date:  2022-01-18       Impact factor: 4.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.